How were Noxopharm's earnings last quarter?

Noxopharm Limited (ASX:NOX) released its quarterly earnings data on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Noxopharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS) , Lincoln Educational Services (LINC) and Immuron (IMRN) .

ASX:NOX

Noxopharm (NOX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free NOX Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 1.23 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Noxopharm alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Noxopharm Stock (ASX:NOX)

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

NOX Stock News Headlines

April 4, 2024 | au.investing.com

FIVE at FIVE AU: ASX up as gold rallies

February 28, 2024 | msn.com

ASX Small Caps Lunch Wrap: Who’s thrown a giant sexy spanner in the works this week?

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

February 17, 2024 | wsj.com

Genetic Technologies Ltd. ADR

February 12, 2024 | au.investing.com

The morning catch up: ASX set to rise; Wall Street mixed as investors await inflation data

February 12, 2024 | au.investing.com

Noxopharm extends strategic partnership with Hudson Institute of Medical Research

February 6, 2024 | afr.com

Noxopharm Limited

January 10, 2024 | proactiveinvestors.com

FIVE at FIVE AU: ASX logs strong day; retail figures better than expected

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

January 1, 2024 | msn.com

ASX December Winners: The best 50 stocks as optimism pushes markets near record high

November 15, 2023 | proactiveinvestors.com

Noxopharm boosts cash position with A$6 million R&D rebate

October 17, 2023 | proactiveinvestors.com

Noxopharm SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation, study shows

October 17, 2023 | msn.com

ASX Health Stocks: Noxopharm jumps +50pc on mRNA vaccine results; Starpharma +25pc on Phase 2 study

October 17, 2023 | proactiveinvestors.com

Noxopharm soars as study shows SOF-VAC asset 'markedly' reduces mRNA vaccine-related inflammation

October 12, 2023 | au.investing.com

Noxopharm and Hudson Institute collaborate on pioneering mRNA research

October 11, 2023 | proactiveinvestors.com

Noxopharm talks partnership with Hudson Institute of Medical Research

October 4, 2023 | msn.com

Closing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastie

October 4, 2023 | msn.com

Market Highlights: Wall Street cops it on strong jobs but who cares when we’ve got all these lovely ASX lithium leads

October 4, 2023 | fool.com.au

ASX healthcare stock Noxopharm explodes 165% on FDA news

October 3, 2023 | proactiveinvestors.com.au

Noxopharm granted US orphan drug status for CRO-67 pancreatic cancer therapy

September 28, 2023 | msn.com

ASX Health Stocks: Anatara moves rapidly to Stage 2 in Phase 1/2 bowel syndrome trial

September 28, 2023 | au.investing.com

Noxopharm presents encouraging data on CRO-67 at AACR Pancreatic Cancer conference

May 25, 2023 | proactiveinvestors.com.au

Noxopharm welcomes preliminary data on Veyonda drug trial

May 22, 2023 | proactiveinvestors.com

Noxopharm hails new Sofra™ drug inflammation results

May 22, 2023 | proactiveinvestors.com.au

Noxopharm welcomes presentation of Sofra™ inflammation technology

May 18, 2023 | msn.com

Market Highlights: FAANG stocks at one-year high, and will US Fed skip a meeting in June?

May 18, 2023 | proactiveinvestors.com.au

Noxopharm reveals new Sofra™ drug reduces inflammation

See More Headlines

Receive NOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2019
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:NOX
CUSIP: N/A
CIK: N/A
Web: www.noxopharm.com
Phone: 61 2 9144 2223
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,130,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -95.95%
Return on Assets: -31.32%

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 12.81
Quick Ratio: 8.43

Sales & Book Value

Annual Sales: $3.88 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 15.42
Book Value: A$0.02 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 292,240,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.71

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Gisela Mautner
CEO, Executive MD & Director
Mr. Shawn Van Boheemen FCPA
J.P., Chief Financial Officer
Ms. Jeanette Bell Ph.D.
Chief Operating Officer
Dr. John Wilkinson B.Sc.
Ph.D., Chief Scientific Officer of Oncology
Dr. Olivier Laczka B.S.
M.Sc., Ph.D., Chief Scientific Officer of Inflammation
Mr. David James Franks BEc (Age 54)
C.A., F Fin, J.P., Company Secretary

Key Competitors

View All Competitors

Insiders

NOX Stock Analysis - Frequently Asked Questions

How were Noxopharm's earnings last quarter?: Noxopharm Limited (ASX:NOX) released its quarterly earnings data on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter.
What other stocks do shareholders of Noxopharm own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS), Lincoln Educational Services (LINC) and Immuron (IMRN).

This page (ASX:NOX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial